Short description
Spinifex Pharmaceuticals is a clinical-stage biotechnology company specializing in the development of products for the treatment of pain.
Description
Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014.
Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.
Last funding
Blurry Noaccess
Sign in for full access
Total funding
$$3123123
Sign in for full access
Location
Preston, Lancashire, United Kingdom, Europe
Founded on
June 1, 2005
Exited on
June 29, 2015
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$56378 - 90123
Sign in for full access
Investors
Noaccess, Cannot Access, Uh Ohhhh, Noaccess, Noaccessforu, No Way
Sign in for full access
Founders
Tom McCarthy